Diabetes insipidus as first manifestation of primary central nervous system lymphoma.
Balmaceda
C M
CM
Department of Neurology, Columbia Presbyterian Medical Center, New York Neurological Institute, NY.
Fetell
M R
MR
Selman
J E
JE
Seplowitz
A J
AJ
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001921:Brain / Q000473:pathology*; D002528:Cerebellar Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000209:etiology* / Q000628:therapy / Q000652:urine; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008223:Lymphoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging; D008297:Male; D013974:Thyroxine / Q000627:therapeutic use; D014667:Vasopressins / Q000652:urine; D017287:Ventriculoperitoneal Shunt; D014750:Vincristine / Q000008:administration & dosage
D014667:Vasopressins; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D003894:Deamino Arginine Vasopressin; D013974:Thyroxine; D006854:Hydrocortisone